Expert Reviews ReDOS Trial Results in mCRC
Tanios Bekaii-Saab, MD, professor of medicine at the Mayo Clinic, discusses results of the ReDOS trial. In the trial, investigators compared 2 arms with different dosing strategies for regorafenib in patients with metastatic colorectal cancer.
Tanios Bekaii-Saab, MD, professor of medicine at the Mayo Clinic, discusses results of the ReDOS trial. In the trial, investigators compared 2 arms with different dosing strategies for regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Investigators gave 1 arm a dose escalation of regorafenib from 80 mg in the first week to 120 mg in the second week, followed by another escalation in the third week to the standard dose of 160 mg. The other arm received the standard dose of 160 mg. This was a positive trial as the investigators’ primary endpoint was reached.
There was a statistically significant difference between the 2 arms, suggesting the escalation dose was superior to the standard.
